{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-014708","form_type":"8-K","ticker":"XLO","cik":"0001840233","company_name":"Xilio Therapeutics, Inc.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.652096+00:00","generated_at":"2026-06-11T12:34:52.485298+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Xilio Therapeutics announces Roche collaboration for XTX101 in MSS CRC; cash $75.4M","bullets":["Entered clinical trial collaboration with Roche; Xilio retains rights to XTX101; eligible for cost-sharing payments.","Updated XTX101 data: durable partial response 36 wks in NSCLC; no Grade 4/5 AEs at RP2D; no colitis.","XTX202 cleared 2.8 mg/kg dose, no vascular leak; expects preliminary Phase 1/2 data early Nov 2023 in ≥20 evaluable pts.","Q2 net loss $19.4M vs $24.6M YoY; cash $75.4M, runway into Q2 2024.","Promoted Chris Frankenfield to COO; XTX301 safety data expected Q4 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-014708","json":"https://secwatch.observer/filing/0001558370-23-014708.json","markdown":"https://secwatch.observer/filing/0001558370-23-014708.md","text":"https://secwatch.observer/filing/0001558370-23-014708.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840233/000155837023014708/0001558370-23-014708-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840233/000155837023014708/xlo-20230814x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T12:34:52.485298+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a1b764b4373b645d88c1b5f7e430354577ff9a63","claim":"Xilio Therapeutics, Inc. reported financial results for the second quarter ended June 30, 2023.","evidence_excerpt":"On August 14, 2023, Xilio Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2023 and other business highlights.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840233/000155837023014708/0001558370-23-014708-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}